Industry Symposia

Wednesday 30th August 

Sanofi Breakfast Symposium

Time: 7.00am to 8.00am

Title: What is the role of PCSK9 Inhibitors in Patients with Diabetes and Cardiovascular Disease?

Content: Diabetes has been recognised as an independent risk factor for cardiovascular disease (CVD) and is often accompanied by other CVD risk factors. This clustering of risk factors for CVD and diagnosis of diabetes can present a complex management challenge. People living with diabetes are often diagnosed with CVD and its complications at a younger age. Large vessel disease, such as coronary heart disease and stroke, represent the leading cause of mortality and morbidity in people living with diabetes. Management of elevated lipids is a persistent challenge in the clinical setting, with those at highest risk for CVD not always achieving appropriate lipids levels with current treatment therapies. Can recent advances in treatments, such as PCSK9 inhibitors, change the way we manage people living with diabetes and cardiovascular disease?

Topic 1: Lipid Management in patients with Diabetes at High Cardiovascular risk.  What are the unmet needs?

Topic 2: Alirocumab versus Usual Care in Diabetes with Hypercholesterolaemia— A look inside the ODYSSEY Diabetes program

Speakers: TBC 

Chair: TBC

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

This session is supported and organised by 

Sanofi Logo

 

Thursday 31st August 

Novo Nordisk Breakfast Symposium

Time: 7.00am to 8.00am

Title: The role of modern insulins and technology in the management of Type 1 and Type 2 diabetes: An ever evolving landscape

Content: The type 2 diabetes treatment landscape is constantly changing in terms of the availability of new clinical data and new classes of glucose lowering therapies. As a result, treatment guidelines, TGA indications and PBS restrictions are also in a state of constant evolution. Given this changing landscape and availability of modern insulins, where insulin fits into the current management of T2D and how can it be used in conjunction with other glucose lowering therapies, is challenging to elucidate. There have also been significant advances in the type 1 diabetes space with new insulins and devices evolving and better able to more closely mimic the physiological response of a person without diabetes, after a meal. 

This symposium will focus on balancing efficacy and safety when using modern insulins alone or in combination with other glucose lowering agents to manage type 2 diabetes and advances in treatments for type 1 diabetes including pumps, closed loop systems, artificial pancreas and new insulins

Topic 1: Use of modern insulin in combination with other glucose lowering agents to manage type 2 diabetes

Topic 2: When is insulin therapy most appropriate for managing type 2 diabetes?

Topic 3: Advancements in treatments for type 1 diabetes including pumps, closed loop systems, artificial pancreas, new insulins

Speakers: Dr Ted Wu and Professor Tim Jones 

Chair: Professor Timothy Davis (Consultant Physician and Endocrinologist, Fremantle Hospital)


This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.



This session is supported and organised by  

novo nordisk high

 

Lilly BI Breakfast Symposium

Time: 7.00am to 8.00am

Title: Glucose lowering and end organ protection in Diabetes.

Content: The advent of new classes of glucose lowering drugs has led to a change in the therapeutic landscape of type 2 diabetes.  The SGLT2 inhibitors have been shown in clinical trials to not only reduce HbA1c but to promote weight loss and decrease blood pressure without being associated with hyperglycaemia when given as monotherapy or with metformin. The recent seminal EMPA-REG trial, with 2 publications in the New England Journal of Medicine has demonstrated that this class of drugs can confer both cardiovascular and renal benefits among sub-groups of the population with Type 2 diabetes. This symposium will renew the latest finding from this trial and address potential pathophysiological mechanisms which could mediate some of the benefits seen with these agents.  This will include a particular focus on renal physiological mechanisms including effects on tubuloglomerular feedback and intraglomerular pressure.  Finally, the findings will be interpreted in terms of recent changes in the guidelines and listings of SGLT2 inhibitors worldwide including in Australia, Canada and the USA.

Topic 1: Mechanisms of action of SGLT2 inhibitors.           

Topic 2: Focus on renal actions of these drugs.          

Speakers: Professor David Cherney and Professor Merlin Thomas

Chair: Mark Cooper (Head- Diabetes Department in the central school at Monash University)


This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.



This session is supported and organised by  

Lilly BI

Sanofi Breakfast Symposium

Time: 7.00am to 8.00am

Title: Clinical Effectiveness and Outcome Studies with Real-World Data – The Australian Opportunities

Content: Real World Evidence: What is it? How does it differ from randomised controlled trials? What can it tell us?Real-world evidence has the potential to complement the information gained from traditional clinical trials, whose well-known limitations make it difficult to generalize findings to larger, more diverse populations of patients, providers, and health care delivery systems. Let’s explore the utility of Real World Data, how it can add to our understanding of glycaemic management and how we can apply it in the Australian context.

Topic 1: TBC

Topic 2: TBC

Speakers: Prof Sanjoy Paul

Chair: TBC

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

This session is supported and organised by 

Sanofi Logo

Friday 1st September

Bayer Breakfast Symposium

Time: 7.30am to 8.30am

Title: Eye health in diabetics: looking at vision, not just blood glucose

Content: Eye health is an important aspect that needs to be considered for effective management of diabetic patients. Ocular complications in diabetic patients are a significant cause of irreversible blindness globally. The fact that diabetes often occurs in working-age Australians underscores the importance of preserving vision to minimize the economic impact and maintain quality-of life in these individuals. The statistics however indicate that a significant proportion of ocular complications arising from diabetes remain undiagnosed until later stages when some degree of the vision loss may be permanent. The good news however, is that with regular screening, prompt diagnosis and early treatment when indicated, almost all vision loss due to diabetes may be prevented.

In this symposium, Dr. Chandra Balaratnasingham of the Lions Eye Institute will discuss diabetic retinal diseases. The symposium will cover the prevalence of diabetic retinal disease, screening, diagnosis and treatment approaches of diabetic ocular complications. Dr. Balaratnasingham will also cover the latest advances in imaging and treatment of diabetic retinopathies. The participants will also have the opportunity to pose questions and discuss the topics with Dr. Balaratnasingham.

Speakers: Professor Sanjoy Paul, Lions Eye Institute: Laser Vision Centre

Chair: TBC

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

This session is supported and organised by 

Bayer Logo